Selected article for: "adaptive innate immune cell and immune cell"
Author: Rowlands, Marianna; Segal, Florencia; Hartl, Dominik
Title: Myeloid-Derived Suppressor Cells as a Potential Biomarker and Therapeutic Target in COVID-19
  • Cord-id: v2r7dw1o
  • Document date: 2021_6_18
    • ID: v2r7dw1o
    Snippet: Clinical presentations of COVID-19 are highly variable, yet the precise mechanisms that govern the pathophysiology of different disease courses remain poorly defined. Across the spectrum of disease severity, COVID-19 impairs both innate and adaptive host immune responses by activating innate immune cell recruitment, while resulting in low lymphocyte counts. Recently, several reports have shown that patients with severe COVID-19 exhibit a dysregulated myeloid cell compartment, with increased myel
    Document: Clinical presentations of COVID-19 are highly variable, yet the precise mechanisms that govern the pathophysiology of different disease courses remain poorly defined. Across the spectrum of disease severity, COVID-19 impairs both innate and adaptive host immune responses by activating innate immune cell recruitment, while resulting in low lymphocyte counts. Recently, several reports have shown that patients with severe COVID-19 exhibit a dysregulated myeloid cell compartment, with increased myeloid-derived suppressor cells (MDSCs) correlating with disease severity. MDSCs, in turn, promote virus survival by suppressing T-cell responses and driving a highly pro-inflammatory state through the secretion of various mediators of immune activation. Here, we summarize the evidence on MDSCs and myeloid cell dysregulation in COVID-19 infection and discuss the potential of MDSCs as biomarkers and therapeutic targets in COVID-19 pneumonia and associated disease.

    Search related documents:
    Co phrase search for related documents
    • active infection and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • active infection and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and acute viral infection: 1, 2, 3, 4, 5
    • active infection and adaptive immune response: 1, 2, 3, 4, 5
    • active infection and adaptive immune system: 1
    • active infection and adaptive innate: 1, 2, 3, 4, 5
    • active infection and lung blood: 1, 2
    • active infection and lung epithelial cell: 1
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and lymphocyte neutrophil: 1, 2, 3, 4
    • active infection and lymphocyte neutrophil ratio: 1, 2, 3, 4
    • active infection and lymphoid cell: 1, 2
    • acute patient and lung blood: 1, 2, 3, 4
    • acute patient and lung infiltration: 1, 2, 3
    • acute patient and lung inflammation: 1, 2
    • acute patient and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8
    • acute patient and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6
    • acute patient and lymphocyte neutrophil ratio: 1, 2, 3, 4, 5